typical seasonal allergic rhinitis during the cedar and cypress pollen seasons
Conditions
Interventions
arm A: Rupatadine 10mg administered to 15 subjects once daily at Japanese cedar pollen exposure.
The next day (at cypress pollen exposure), also Rupatadine 10mg administered once daily.
arm B: Rupata
Sponsors
Hashiguchi Kazuhiro
Mitsubishi Tanabe Pharma Corporation
Teikoku Seiyaku Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients between 20 and 60 years old (at the time of consent). Male and female. 2) Patients with specific IgE positive (class 2 to 6) against cedar pollen and cypress pollen allergens. 3) Patients who have typical seasonal allergic rhinitis during the cedar and cypress pollen seasons, for the past 2 years. 4) Patients judged as eligible by the doctor as a result of medical examination. 5) Patients who obtained consent for study participation. 6) Patients developed with nasal allergy symptoms by exposure to cedar pollen and cypress pollen in screening.
Exclusion criteria
Exclusion criteria: 1) Patients with nasal disease that affects the evaluation of the study. 2) Patients complicated with perennial allergic rhinitis that is severe or needs treatment. 3) Patients who received steroid injection within 6 months before consent. 4) Patients who have received hay fever immunotherapy within 3 years before consent. 5) Patients with respiratory diseases such as bronchial asthma. 6) Patients with a history of anaphylaxis. 7) Patients who have hypersensitivity to rupatadine. 8) Patients who can not avoid taking anti-allergic drugs or treating allergy after consent. 9) Pregnant woman, lactating woman, patients who may be pregnant, or patients who plan to pregnant. 10) Patients who have participated in another clinical study within 3 months before consent. 11) Patients who the doctor judged inappropriate for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time course of Total Nasal symptoms score (nasal discharge, sneezing, nasal obstruction) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time course of each Nasal symptoms score(nasal discharge, sneezing, nasal obstruction) Time course of each itching score (eye,nose) Sneezing number of times Quantity of nasal discharge | — |
Contacts
Public ContactKazuhiro Hashiguchi
Shinanozaka Clinic
Outcome results
None listed